Two targeted therapies (Olaparib and Pluvicto) have been developed for the treatment of men with advanced prostate cancer. Both extend life and offer a better quality of life with milder side effects of treatment.
These “precision” treatments specifically target and destroy cancer cells, wherever they are in the patient’s body, unlike chemotherapy that can cause damage to healthy cells. Both offer a better quality of life with milder side effects of treatment than chemotherapy. Both could be prescribed for men who are not suitable for chemotherapy.
The National Institute for Health and Care Excellence (NICE) makes a decision about whether or not NHS access to new treatments should be granted in England and Wales. Neither Olaparib nor Pluvicto have been recommended so far, and a final decision on Pluvicto is expected in January 2023.
Every day, 33 men in the UK lose their lives to prostate cancer. These new drugs could make all the difference, giving quality time back to these men and their families.